155 related articles for article (PubMed ID: 19738018)
1. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Adam HJ; Laing NM; King CR; Lulashnyk B; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2009 Nov; 53(11):4915-20. PubMed ID: 19738018
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
[TBL] [Abstract][Full Text] [Related]
4. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
8. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
Li ZX; Liu YN; Wang R; Li AM
Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
Hoogkamp-Korstanje JA; Roelofs-Willemse J
J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the new quinolone WCK 771 against staphylococci.
Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Wakabayashi E; Mitsuhashi S
Antimicrob Agents Chemother; 1994 Mar; 38(3):594-601. PubMed ID: 8203860
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
[TBL] [Abstract][Full Text] [Related]
17. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of HSR-903, a new quinolone.
Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
[TBL] [Abstract][Full Text] [Related]
19. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
Bongaerts GP; Hoogkamp-Korstanje JA
Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
